References

1. Alting Von Geusau N, Stalenhoef, P, Huizinga M, Snel J, Ridderinkhof KR (2004) Impaired executive function in male MDMA (Ecstasy) users. Psychopharmacology (Berl), Published online March 18, 2004. DOI: 10.1007/s00213-004-1832-1838.
2. Baggott M, Jerome L, Stuart R (2001) 3,4-Methylenedioxymethamphetamine (MDMA) A Review of the English-Language Scientific and Medical Literature. Published on-line: http://www.maps.org/research/mdma/protocol/litreview.html.
3. Bateman DN, McElhatton PR, Dickinson D, Wren C, Matthews JN, O'Keeffe M, Thomas SH (2004) A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England. Eur J Clin Pharmacol 60: 635-641.
4. Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E (2000) Ecstasy-induced toxicity in rat liver. Liver 20: 8-15.
5. Bexis S, Phillis BD, Ong J, White JM, Irvine RJ (2004) Baclofen prevents MDMA- induced rise in core body temperature in rats. Drug Alcohol Depend 74: 89-96.
6. Bhattachary S, Powell JH (2001) Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': Evidence for cognitive impairment. Psychological Med 31:647-658.
7. Blessing WW, Seaman B, Pedersen NP, Ootsuka (2003) Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4- methylenedioxymethamphetamine (ecstasy) in rabbits and rats J Neurosci 23: 6385-6389.
8. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537.
9. Bond AJ, Verheyden SL, Wingrove J, Curran HV (2004) Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacol (Berl) 171: 331- 339.
10. Bouso JC (2004) Personal communication to Rick Doblin PhD and Lisa Jerome PhD., January 15, 2003.
11. Brown PL, Kiyatkin EA. (2004) Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci. 20: 51-58.
12. Broening HW, Bowyer JF, Slikker W Jr (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4- methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response J Pharmacol Exp Ther 275: 325-333.
13. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV (2001) 3,4- Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development Journal of Neuroscience 21: 3228-3225.
14. Brookhuis KA, De Waard D, Samyn N. (2004) Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology (Berl) 173: 440-444.
15. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "Ecstasy" use Lit Review Update 2004 48 References on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375- 384.
16. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161:1181-1189.
17. Bull EJ, Hutson PH, Fone KC (2003) Reduced social interaction following 3,4- methylenedioxymethamphetamine is not associated with enhanced 5-HT(2C) receptor responsivity Neuropharmacology 44: 439-448.
18. Bull EJ, Hutson PH, Fone KC. (2004) Decreased social behaviour following 3,4- methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5- HT(2A) receptor responsivity. Neuropharmacology. 46: 202-210. Butler GK, Montgomery AM (2004) mpulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alcohol Depend 76: 55-62.
19. Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-121.
20. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466.
21. Carvalho M, Carvalho F, Remiao F, de Lourdes Pereira M, Pires-Das-Neves R, de Lourdes Bastos M (2002). Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76: 166-172.
22. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, Monks TJ, Carvalho F, Bastos ML. (2003) Hepatotoxicity of 3,4- methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78:16-24.
23. Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users. J Magn Reson Imaging 10: 521-526.
24. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS (2004) MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 173: 318-325.
25. Cohen RS (1995) Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 19: 1137-1145.
26. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997) A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy Br J Pharmacol 121: 827-833.
27. Cole JC, Sumnall HR (2003A) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98:35-58.
28. Cole JC, Sumnall HR (2003B) The pre-clinical behavioural pharmacology of 3,4- methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199- 217.
29. Connor TJ, Kelly JP, McGee M, Leonard BE (2000b) Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge. Life Sci 67: 1601-1612.
30. Connor TJ, Harkin A, Kelly JP (2005) Methylenedioxymethamphetamine (MDMA; "Ecstasy") suppresses production of the pro-inflammatory cytokine tumor necrosis factor-{alpha} independent of a {beta}-adrenoceptor-mediated increase in interleukin-10. J Pharmacol Exp Ther 312(1): 134-143
31. Cottler L, Womack SB, Compton WM, Ben-Abdallah A (2001). Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Human Psychopharmacology, Clinical and Experimental, 16; 599-606.
32. Curran HV, Verheyden SL (2003) Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacol (Berl) 169: 91-103.
33. Curran HV, Rees H, Hoare T, Hoshi R, Bond A. (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology (Berl) 173: 425-433. Epub 2004 Jan 20.
34. Dafters RI, Hoshi R, Talbot AC (2004) Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacol (Berl) 173: 405-410.
35. Daniela E, Brennan K, Gittings D, Hely L, Schenk S (2004) . Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 77: 745-750.
36. Darvesh AS, Gudelsky GA (2004) The relationship between hyperthermia and glycogenolysis in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats. Neurotoxicol Teratol 26: 571-577.
37. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 16 :627-633.
38. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004A) Self- reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacol (Berl) 173 :398-404.
39. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E (2004B) Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4- methylenedioxymethamphetamine) users. Psychopharmacology (Berl) Sep 2004 15,Published on-line.
40. Daumann J, Fischermann T, Pilatus U, Thron A, Moeller-Hartmann W, Gouzoulis- Mayfrank E (2004C) Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci Lett 362:113-116.
41. Daumann J, Fischermann T, Heekeren K, Thron A, Gouzoulis-Mayfrank E (2004D) Neural Mechanisms of Working Memory in Ecstasy (MDMA) Users Who Continue or Discontinue Ecstasy and Amphetamine Use: Evidence from an 18- Month Longitudinal functional magnetic resonance imaging Study. Biol Psychiatry 56: 349-355.
42. de Almeida SP, Silva MT (2003) Ecstasy (MDMA): effects and patterns of use reported by users in Sao Paulo Rev Bras Psiquiatr 25 :11-17.
43. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
44. de la Torre R, Farre M. (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci. 25: 505-508.
45. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 26: 137-144.
46. De Win MM, Reneman L, Reitsma JB, Den Heeten GJ, Booij J, Van Den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 173: 376-382.
47. Duarte JA, Leão A, Magalhães J, Ascensão A, Bastos ML, Amado FL, Vilarinho L, Quelhas D, Appell HJ, Carvalho F (2005) Strenuous exercise aggravates MDMA- induced skeletal muscle damage in mice. Toxicology 206: 349-358.
48. Dumasia MC. (2003) Identification of some N-hydroxylated metabolites of (+/-)-3,4- methylenedioxymethamphetamine in horse urine by gas chromatography-mass spectrometry. Xenobiotica. 33: 1013-1025. Cited in Keizers et al. 2004.
49. Escobedo I, O'shea E, Orio L, Sanchez V, Segura M, de la Torre R, Farre M, Green AR, Colado M (2005) A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 144: 231-241.
50. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4- Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) 161: 356-364.
51. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH (2003) Pharmacological characterization of the effects of 3,4- methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166: 202-211.
52. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G. (2004) Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys. Neuropsychopharmacology. Published electronically Feb 16 2004.
53. Farre M, De La Torre R, O Mathuna B, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:3 64-375.
54. Fisk JE, Montgomery C, Murphy P, Wareing MEvidence for executive deficits among users of MDMA (Ecstasy). Br J Psychol 95: 457-466. Lit Review Update 2004 51 References
55. Fone KCF, Beckett SRC, Topham IA, Swettenham J, Ball M, Maddocks L (2002). Long- term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl), 159: 437-444.
56. Fornai F, Lenzi P, Frenzilli G, Gesi M, Ferrucci M, Lazzeri G, Biagioni F, Nigro M, Falleni A, Giusiani M, Pellegrini A, Blandini F, Ruggieri S, Paparelli A. (2004) DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berl) 173:353-363.
57. Forsling M, Fallon JA, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4- methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J Pharmacy Pharmacol 53: 1357-1363.
58. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl) 162:203-214.
59. Frederick DL, Ali SF, Slikker W Jr, Gillam MP, Allen RR, Paule MG (1995) Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys Neurotoxicol Teratol 17: 531-534.
60. Frederick DL, Paule MG (1997) Effects of MDMA on complex brain function in laboratory animals Neurosci Biobehav Rev 21: 67-78.
61. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX (2001)Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 14: 152-165.
62. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. (2000) 3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388-395. Erratum in: Neuropsychopharmacology 23(5):following 598. Hell, D [corrected to Liechti, ME].
63. Gamma A, Lehmann D, Frei E, Iwata K, Pascual-Marqui RD, Vollenweider FX (2004) Comparison of simultaneously recorded [H2(15)O]-PET and LORETA during cognitive and pharmacological activation. Hum Brain Mapp 22: 83-96.
64. Garcia-Osta A, Del Rí¯ J, Frechilla D (2004) Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. Brain Res Mol Brain Res 126: 181-187.
65. Gerra G, Zaimovic A, Ampollini R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F (2001) Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates. J Subst Abuse 13: 471-491.
66. Gesi M, Lenzi P, Soldani P, Ferrucci M, Giusiani A, Fornai F, Paparelli A (2002) Morphological effects in the mouse myocardium after methylenedioxymethamphetamine administration combined with loud noise exposure Anat Rec 267: 37-46.
67. Gesi M, Ferrucci M, Giusiani M, Lenzi P, Lazzeri G, Alessandrì MG, Salvadorini A, Fulceri F, Pellegrini A, Fornai F, Paparelli A (2004) Loud noise enhances nigrostriatal dopamine toxicity induced by MDMA in mice. Microsc Res Tech 64: 297-303.
68. Gilhooly TC, Daly AK (2002) CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54: 69-70.
69. Gijsman HJ, Van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, Hessing TJ, Cohen AF (2002) Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. Hum Psychopharmacology 17: 83-89.
70. Gouzoulis-Mayfrank, E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68: 719-725.
71. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hansen G, Daumann J (2003) Memory impairments suggest hippocampal dysfunction in abstinent Ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27: 819-827.
72. Green AR, McGregor IS (2002) On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology (Berl) 162 :448-50.
73. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. (2003B) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
74. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4- methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73:103-107.
75. Grob CS, Poland RE, Boone KB (unpublished) Psychological, physiological and neuroendocrine effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in healthy humans. Data presented in Investigators' Brochure.
76. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JH, Yurgelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147,
77. Hanson KL and Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229-246.
78. Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl) 162: 396-405.
79. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M (1998) Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 351: 1784.
80. Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA (2005) Role of the serotonin 5- HT(2A) receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4- methylenedioxymethamphetamine. Psychopharmacology (Berl) 178: 505-513.
81. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A. (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32: 1213-1217.
82. Ho E, Karimi-Tabesh L, Koren G (2001). Characteristics of pregnant women who use Ecstasy (3, 4- methylenedioxymethamphetamine). Neurotoxicol Teratol 23: 561- 567.
83. Ho YJ, Pawlak CR, Guo L, Schwarting RK (2004) . Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res 149: 135-144.
84. Hoshi R, Bisla J, Curran HV (2004) The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings. Drug Alcohol Depend 76: 297-304.
85. Hrometz SL, Brown AW, Nichols DE, Sprague J (2004) 3,4- methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin- reuptake transporter, and monoamine oxidase-B. Neurosci Lett 367: 56-59.
86. Jerome L, Baggott M (2003) MAPS' MDMA Investigator's Brochure Update #1 A Review of Research in Humans and Non-Human Animals. Published on-line at http://www.maps.org/research/mdma/protocol/litupdate1.pdf/.
87. Jerome L (2004) MAPS' MDMA investigator's brochure update #2; A review of research in humans and non-human animals. Published on-line: http://www.maps.org/research/mdma/protocol/litupdate2.pdf/.
88. Kalasinsky KS, Hugel J, Kish SJ (2004) Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 49: 1106-1112.
89. Keizers PH, Lussenburg BM, de Graaf C, Mentink LM, Vermeulen NP, Commandeur JN (2004) Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)- coumarin metabolism. Biochem Pharmacol 68: 2263-2227.
90. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137: 963-970.
91. Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. (2003A) Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol 25: 509-517.
92. Koprich JB, Campbell NG, Lipton JW. (2003B) Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Res Dev Brain Res Dec 147: 177-182.
93. Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59: 1563-1571.
94. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4- methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18: 331-341.
95. Lamers CTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17:379-387.
96. Lanz M, Brenneisen R, Thormann W (1997) Enantioselective determination of 3,4- methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 18: 1035- 1043.
97. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 133: 969-973.
98. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68:195-207.
99. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 22: 513-521.
100. Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4- methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14: 269-274.
101. Liechti ME, Gamma A, Vollenweider FX (2001a) Gender differences in the subjective effects of MDMA. Psychopharmacol 154:161-168.
102. Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4- methylenedioxymethamphetamine use. J Nerv Ment Dis 180: 345-52; discussion 345-352.
103. Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans. Biol Psychiatry 53 (Suppl); 205S. Data presented at the 58th Annual Conference of the Society for Biological Psychiatry, San Francisco, CA.
104. Malberg JE, Sabol KE, Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat J Pharmacol Exp Ther 278: 258-267.
105. Malberg JE, Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat J Neurosci 18: 5086-5094.
106. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner (1999) Acute toxicity of 3,4- methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats Pharmacol Biochem Behav 64: 29-34.
107. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136- 145.
108. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
109. McCann U, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in 3,4- methylenedioxymethamphetamine (MDMA) users: A controlled study. Psychopharmacol 143:417-425.
110. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 173: 434-439.
111. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999) Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
112. McGregor IS, Clemens KJ, Van Der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003A) Increased Anxiety 3 Months after Brief Exposure to MDMA ('Ecstasy') in Rats: Association with Altered 5-HT Transporter and Receptor Density Neuropsychopharmacology 28: 1472-1484.
113. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt G (2003B) Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes Psychopharmacology (Berl) 168:465-474.
114. Meyer JS, Ali SF (2002) Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain Ann N Y Acad Sci 965: 373-380.
115. Meyer A, Mayerhofer A, Kovar K, Schmidt W (2002) Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4- methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats Neurosci Lett 330: 280-284.
116. Milani RM, Parrott AC, Turner JJ, Fox (2004) Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 29: 965-971.
117. Mills EM, Banks ML, Sprague JE, Finkel T. (2003) Pharmacology: uncoupling the agony from ecstasy. Nature 426: 403-404.
118. Mills EM, Rusyniak DE, Sprague J (2004) The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4- methylenedioxymethamphetamine. J Mol Med 82: 787-799.
119. Mithoefer M (2005) Personal communication to Rick Doblin PhD and Lisa Jerome PhD; electronic mail sent February 17, 2005.
120. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacol (Berl) 141: 30-36.
121. Ninkovic M, Malicevic Z, Selakovic V, Simic I, Vasiljevic I. (2004) N-methyl-3,4- methylenedioxyamphetamine-induced hepatotoxicity in rats: oxidative stress after acute and chronic administration. Vojnosanit Pregl 61: 125-131.
122. Obergriesser T, Ende G, Braus DF, Henn FA (2001) Hippocampal [1H]-MRSI in ecstasy users. European Archives of Psychiatry and Clinical Neuroscience 251: 114-116
123. O'Donohoe A, O'Flynn K, Shields K, Hawi Z, Gill M (1998) MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. Addiction Biology 3:309-314.
124. O'Regan MC, Clow A (2004) Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology (Berl). 173:446-451. Epub 2004 Jan 30.
125. O'Suilleabhain P, Giller C. (2003) Rapidly progressive parkinsonism in a self- reported user of Ecstasy and other drugs. Mov Disord. 2003 Nov;18(11):1378- 1381.
126. Ootsuka Y, Nalivaiko E, Blessing WW (2004) Spinal 5-HT2A receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasoconstriction elicited by MDMA (3,4- methylenedioxymethamphetamine, "Ecstasy") and its reversal by clozapine. Brain Res 1014: 34-44.
127. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado M (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89: 1445- 1453.
128. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Hernandez Lopez C,
129. Ortuno J, Segura J, Cami J, de la Torre R (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914: 215-224.
130. Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296: 207-215.
131. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965:421-433.
132. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset P, Segura J, De La Torre R (2004) Paroxetine inhibits acute effects of MDMA on the immune system in humans. J Pharmacol Exp Ther 309:285-292. Parrott AC, Sisk E, Turner JJ (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110.
133. Parrott AC (2004) . MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50: 329-335.
134. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4- methylenedioxymethamphetamine in recreational users Neuropsychopharmacology 1: 273-277.
135. Piper BJ, Meyer JS (2004) Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79: 723-731.
136. Pizarro N, Llebaria A, Cano S, Joglar J, Farre M, Segura J, de la Torre R (2003) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:330-336.
137. Pizarro N, Farré M, Pujadas M, Peiró AM, Roset PN, Joglar J, De La Torre R (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4- dihydroxymethamphetamine). Drug Metab Dispos 32: 1001-1007.
138. Reneman L, Booij K, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001A) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864-1869.
139. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij (2001B) cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-Methylenedioxymethamphetamine (MDMA or 'Ecstasy'): Preliminary findings. Archives of General Psychiatry 58: 901-906.
140. Reneman L, Majoie CBLM, Schmand B, van den Brink W, den Heeten GJ (2001C) Pre- frontal N-acetylaspartate is strongly associated with memory performance in (abstinent) Ecstasy users: Preliminary report. Biological Psychiatry 50: 550-554.
141. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff F, Booij J (2002A). The acute and chronic effects of MDMA ("Ecstasy") on cortical 5HT2A receptors in rat and human brain. Neuropsychopharmacol 26:387-396.
142. Reneman L, Majoie CB, Flick H, den Heeten GJ (2002B) Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results. AJNR Am J Neuroradiol 23:231-237.
143. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297:2260-2263.
144. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003) Retraction. Science 301:1479.
145. Robledo P, Balerio G, Berrendero F, Maldonado R. (2004A) Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 369:338-349.
146. Robledo P, Mendizabal V, Ortuno S, de la Torre R, Kieffer BL, Maldonado R (2004B) The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur J Neurosci 20: 853-858.
147. Rodgers J (2000) Cognitive performance amongst recreational users of 'ecstasy' . Psychopharmacology (Berl) 151: 19-24.
148. Rosa-Neto P, Olsen AK, Gjedde A, Watanabe H, Cumming P (2004) MDMA-evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia. Synapse 53: 214-221.
149. Rusyniak DE, Tandy SL, Kamendulis LM, Sprague JE, Klaunig JE (2004) The effects of ecstasy (MDMA) on rat liver bioenergetics. Acad Emerg Med 11: 723-729.
150. Samyn N, De Boeck G, Wood M, Lamers C, De Waard D, Brookhuis K, Verstraete A, Riedel W (2002) Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128: 90-97.
151. Sanchez V, O'shea E, Saadat KS, Elliott JM, Colado MI, Green AR (2004) Effect of Repeated ('Binge') Dosing of MDMA to Rats Housed at Normal and High Temperature on Neurotoxicdamage to Cerebral 5-HT and Dopamine Neurones. J Psychopharmacol 18: 412-416.
152. Schenk S, Gittings D, Johnstone M, Daniela E (2003) Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169: 21-27.
153. Schifano F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G, Ghodse A (2003) Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002 Hum Psychopharmacol 18 : 519-524.
154. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974: 127-133.
155. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2004) . Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 29: 743-752.
156. Seiden LS, Woolverton WL, Lorens SA, Williams JEG, Corwin RL, Hata N, Olimski M (1993) . Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: the conflict between pharmacology and toxicology NIDA Res Monogr 136: 34-46.
157. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63: 1223-1229.
158. Simon NG, Mattick RP (2002) The impact of regular Ecstasy use on memory function. Addiction 97:1523-1529.
159. Singer LT, Linares TJ, Ntiri S, Henry R, Minnes S (2004) . Psychosocial profiles of older adolescent MDMA users. Drug Alcohol Depend 74: 245-152.
160. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug. Br J Addict 87: 1161-1172.
161. Sprague JE, Banks ML, Cook VJ, Mills EM. (2003) Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4- methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305: 159- 166.
162. Sumnall HR, Wagstaff GF, Cole JC (2004A) Self-reported psychopathology in polydrug users. J Psychopharmacol 18: 75-82.
163. Sumnall HR, O'Shea E, Marsden CA, Cole JC (2004B) The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test. Pharmacol Biochem Behav 77: 805-814.
164. Sveen ML, Knudsen GM, Aznar S (2004) No effect of MDMA (ecstasy) on cell death and 5-HT2A receptor density in organotypic rat hippocampal cultures. Neurosci Lett 362: 6-9.
165. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH (2002) Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge Neuropsychopharmacology 27: 993-1005.
166. Taffe MA, Huitron-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, Gold LH (2003) MDMA exposure alters cognitive and electrophysiological sensitivity to rapid tryptophan depletion in rhesus monkeys Pharmacol Biochem Behav 76: 141-152.
167. Tancer ME, Johnson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65: 97-101.
168. Tancer M, Johanson C-E (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33-44.
169. Tancer ME, Johanson C-E (2004) The effects of fluoxetine response to MDMA, mCPP and d-amphetamine in humans. Poster presented at College on Problems of Drug Dependence Conference, San Juan, Puerto Rico, CPDD Abstracts.
170. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacol (Berl) 167:85-96.
171. Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL, McGregor IS (2004) Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology 29: 694-704.
172. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
173. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994). he demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47: 1151-1156.
174. van de Wijngaart GF, Braam R, de Bruin D, Fris M, Maalste NJM, Verbraeck HT (2001) Ecstasy use at large-scale dance events in the Netherlands.J Drug Issues 29: 679- 702.
175. Varela-Rey M, Montiel-Duarte C, Beitia G, Cenarruzabeitia E, Iraburu MJ (1999) 3,4- methylenedioxymethamphetamine ("Ecstasy") stimulates the expression of alpha1(I) procollagen mRNA in hepatic stellate cells. Biochem Biophys Res Commun 259: 678-682.
176. Verbaten MN (2003) Specific memory deficits in ecstasy users? The results of a meta- analysis. Hum Psychopharmacol 18: 281-290.
177. Verdejo-Garcia AJ, Lopez-Torrecillas F, Aguilar de Arcos F, Perez-Garcia M. (2005)Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav 30: 89-101.
178. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, De Visser S, Kuijerps M, Pennings EJM, de Bruin D, van de Wijngaart G, Van Gerven JM, Cohen A (2000) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacol (Berl) 153:196-202.
179. Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA- naive healthy volunteers. Neuropsychopharmacol 19:241-251.
180. Vollenweider FX, Gucker P, Schönbächler R, Kamber E, Vollenweider-Scherpenhuyzen MFI, Schubiger G, Hell D (2000) Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft für psychiatrie, Psychotherapie und Nervenheilkunde].
181. Vorhees CV, Reed TM, Skelton MR, Williams MT (2004) Exposure to 3,4- methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning. Int J Dev Neurosci 22: 247-259.
182. Wakonigg G, Sturm K, Saria A, Zernig G. (2003) Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure. Pharmacology 69:180-182. Lit Review Update 2004 60 References
183. Wang X, Baumann MH, Xu H, Rothman RB. (2004) 3,4- methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53:240-248.
184. Wareing M, Fisk JE, Murphy P, Montgomery C (2004A) Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacol 19: 225- 134.
185. Wareing M, Murphy PN, Fisk JE (2004B) Visuospatial memory impairments in users of MDMA ("Ecstasy") Psychopharmacol (Berl) 173:391-397.
186. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV (2003) Developmental 3,4- methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968: 89-101.
187. Winsauer PJ, Quinton MS, Porter JR, Corll CB, Moerschbaecher JM, Delatte MS, Leonard ST, Stroble SB (2004) Effects of MDMA administration on scopolamine-induced disruptions of learning and performance in rats. Pharmacol Biochem Behav 79: 459-472.
188. Wolff K, Winstock A, Hartley DE, Forsling ML (2004) The physiological responses to the use of MDMA whilst clubbing: posterior pituitary function and fluid balance J Physiology 555P C157 Proceedings of the Physiological Society.
189. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53: 1605-1612.
190. Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA (2004) Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4- methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci 24: 7043-7050.
191. Zakzanis KK, Young DA (2001) Memory impairment in abstinent MDMA ("ecstasy") users: A longitudinal investigation. Neurology 56:966-969.